- The Inclusion of a Gemcitabine + Nab-paclitaxel Regimen as a 2nd Line Treatment for Advanced Pancreatic Cancer - First Experience2017 | First Faculty of Medicine
- Gemcitabine - drug profile1995 | Faculty of Pharmacy in Hradec Králové
- Serious cutaneous toxicity following ifosfamide, gemcitabine and vinorelbine therapy in a patient with relapsed Hodgkin lymphoma and ichthyosis]2009 | First Faculty of Medicine
- The Inclusion of a Gemcitabine + Nab-paclitaxel Regimen as a 2nd Line Treatment for Advanced Pancreatic Cancer - First Experience2017 | First Faculty of Medicine, Faculty of Physical Education and Sport
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. 20060540Publication without faculty affiliation
- Gemcitabin and Cisplatin as a treatment of non small cell lung cancer1999 | Faculty of Medicine in Pilsen
- Final report of University Hospital Hradec Kralove to the clinical trial protocol no. PIX306Publication without faculty affiliation
- The Quality of ife in Patients with Lung Tumours and teh Treatment with GemcitabinePublication without faculty affiliation
- Complete remission and long-term response to gemcitabine + nab-paclitaxel in patient with metastatic pancreatic adenocarcinoma2021 | Third Faculty of Medicine
- Gemcitabine plus cisplatin vs. gemcitabine plus carboplatin in stage IIIb and IV non-small cell lung cancer: a phase III randomized trial2003 | First Faculty of Medicine, Faculty of Medicine in Pilsen, Third Faculty of Medicine
- Gemcitabine in non-small cell lung cancer (NSCLC)2000 | Third Faculty of Medicine
- Treatment with Gemcitabine and Cisplatina in Patients with Advanced Stages of Non Small Cell Pulmonary CarcinomasPublication without faculty affiliation
- Gemcitabine/carboplatin in advanced non-small cell lung cancer2002 | First Faculty of Medicine, Third Faculty of Medicine
- Gemcitabine and carboplatin treatment in Patients with relapsing ovarian cancer2009 | Publication without faculty affiliation
- Gemcitabin plus cisplatin versus gemcitabin plus carboplatinPublication without faculty affiliation
- Streptokinase increases the sensitivity of colon cancer cells to chemotherapy by gemcitabine and cis-platine in vitro2006 | Third Faculty of Medicine
- Pixantrone-rituximab versus gemcitabine-rituximab in relapsed/refractory aggressive non-Hodgkin lymphoma2016 | Faculty of Medicine in Hradec Králové
- The Inclusion of a Gemcitabine Nab-paclitaxel Regimen as a 2nd Line Treatment for Advanced Pancreatic Cancer - First Experience2017 | First Faculty of Medicine, Faculty of Physical Education and Sport
- Postavení gemcitabinu v léčbě NSCLCPublication without faculty affiliation
- Chemotherapy in pancreatic carcinoma2019 | Faculty of Medicine in Pilsen
- Gemcitabin plus cisplatin versus gemcitabin plus carboplatin inPublication without faculty affiliation
- A phase III randomized study of gemcitabine and cisplatin with or without PF-3512676 (TLR9 agonist) as first-line treatment of advanced non-small-cell lung cancer2012 | Third Faculty of Medicine
- Pixantrone plus rituximab versus gemcitabine plus rituximab in patients with relapsed aggressive B-cell non-Hodgkin lymphoma not eligible for stem cell transplantation: a phase 3, randomized, multicentre trial (PIX306)2020 | Faculty of Medicine in Hradec Králové
- Phase III Trial of Cisplatin Plus Gemcitabine With Either Placebo or Bevacizumab As First-Line Therapy for Nonsquamous Non-Small-Cell Lung Cancer: AVAiL2009 | Third Faculty of Medicine
- Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial2007 | First Faculty of Medicine, Faculty of Medicine in Pilsen
- Gemcitabine and carboplatin treatment in Patients with relapsing ovarian cancer2009 | Central Library of Charles University
- Gemcitabin v léčbě lokálně pokročilého a nebo metastázujícího karcinomu močového měchýře2001 | Publication without faculty affiliation
- Cationic liposomal paclitaxel plus gemcitabine or gemcitabine alone in patients with advanced pancreatic cancer: a randomized controlled phase II trial2012 | Second Faculty of Medicine
- Are ENT1/ENT1, NOTCH3, and miR-21 Reliable Prognostic Biomarkers in Patients with Resected Pancreatic Adenocarcinoma Treated with Adjuvant Gemcitabine Monotherapy?2019 | Faculty of Pharmacy in Hradec Králové, Faculty of Medicine in Hradec Králové
- Gemcitabine plus cisplatin versus gemcitabine plus carboplatin in patients with NSCLC stage IIIB and IVAn interim analysis2001 | First Faculty of Medicine, Third Faculty of Medicine